ライフサイエンスコーパス: young-onset

1 d by an autosomal dominant inheritance and a young onset.

2 ide linkage scan in Pima Indians indicated a young-onset (aged <45 years) type 2 diabetes susceptibil

3 rich variation in phenotypes among cases of young-onset amyotrophic lateral sclerosis, bulbar onset

4 'Young-onset' amyotrophic lateral sclerosis typically ref

5 ored to the distinct molecular landscapes of young-onset and late-onset CRC.

6 be tailored to a specific diagnosis of both young-onset and late-onset dementia.

7 Young-onset and longer-duration of diabetes increase the

8 utations and determine their contribution in young-onset and more typical later onset Parkinson's dis

9 of African ancestry are more likely to have young-onset and oestrogen receptor (ER) negative breast

10 Young-onset autoimmune diabetes associated with addition

11 neuron disease with TDP-43 type B pathology; young-onset behavioural variant frontotemporal dementia

12 Most multiple case families of young onset breast cancer and ovarian cancer are thought

13 IQR 35.5-49.2]), of whom 8455 (2%) developed young-onset breast cancer (diagnosed before age 55 years

14 num, lead, tin, and vanadium--in relation to young-onset breast cancer (diagnosis age <50 years), whi

15 of any type was not associated with incident young-onset breast cancer (HR 0.96 [95% CI 0.88 to 1.04]

16 se was inversely associated with the risk of young-onset breast cancer (odds ratio = 0.58, 95% confid

17 was not associated with an increased risk of young-onset breast cancer (odds ratio = 0.80, 95% confid

18 In young-onset breast cancer (YOBC), a diagnosis within 5 t

19 but we observed no such association between young-onset breast cancer and toenail concentrations of

20 Oestrogen hormone therapy and young-onset breast cancer association was similar for al

21 proven in 1990 by mapping predisposition to young-onset breast cancer in families to chromosome 17q2

22 n hormone therapy was associated with higher young-onset breast cancer incidence among women with int

23 us progestin HT or unopposed estrogen HT and young-onset breast cancer using data from the Two Sister

24 oestrogen plus progestin hormone therapy and young-onset breast cancer was 1.10 (0.98 to 1.24), with

25 Cumulative risk of young-onset breast cancer was 4.1% in non-users.

26 The association between cadmium and young-onset breast cancer was near null, with no evidenc

27 ne therapy use was inversely associated with young-onset breast cancer, and oestrogen plus progestin

28 sting, previously restricted to familial and young-onset breast cancer, is now offered increasingly b

29 rease accuracy of prognosis in patients with young-onset breast cancer.

30 ssociations of hormone therapy with incident young-onset breast cancer.

31 Young-onset breast cancers (YOBC) tend to be aggressive

32 nd CRC, which has important implications for young onset cancer prevention.

33 eria or prediction models; isolated sporadic young-onset cases can be prescreened by tumor testing, w

34 % of controls versus 15% of cases and 20% of young-onset cases, both highly significant differences.

35 substantial proportion, over-represented in young-onset cases, have atypical phenotypes including pr

36 ants were 13102 patients diagnosed as having young-onset colon adenocarcinoma aged 18 to 49 years and

37 Treatment options for patients with young-onset colon cancer remain to be defined and their

38 However, the prognosis of young-onset colon cancer remains poorly defined given si

39 Most young-onset colon cancer was initially seen at advanced

40 An alarming rise in young onset colorectal cancer (CRC) has been reported; h

41 Increasing rates of young-onset colorectal cancer (CRC) have attracted subst

42 Suspected risk factors of young onset CRC include environmental aspects, such as l

43 We identified 28,145 patients with young-onset CRC (19,497 NHW; 4,384 NHB; 4,264 Hispanic)

44 , which is referred to as early-onset CRC or young-onset CRC (YO-CRC).

45 We compared the survival of young-onset CRC among non-Hispanic black (NHB), non-Hisp

46 we found racial disparities in incidence of young-onset CRC and patient survival for cancer of the c

47 ficant difference in WNT alterations between young-onset CRC and those > 50 years old.

48 We examined racial disparities in young-onset CRC by comparing CRC incidence and relative

49 s of WNT and TGF-Beta pathway alterations in young-onset CRC cases has yet to be investigated.

50 ence demonstrates an increasing incidence of young-onset CRC cases, defined as CRC cases in individua

51 Well-documented and recent increases in young-onset CRC have largely been due to increases in re

52 The underlying risk factors for young-onset cryptogenic ischaemic stroke (CIS) remain un

53 vasive dental treatments are associated with young-onset cryptogenic ischemic stroke (CIS).

54 A diagnosis of young-onset dementia (YOD) is a life-altering event for

55 eliable prevalence estimates are lacking for young-onset dementia (YOD), in which symptoms of dementi

56 Young-onset dementia (YOD), which develops before age 65

57 d information on modifiable risk factors for young-onset dementia (YOD).

58 rtical atrophy typically presents as a pure, young-onset dementia syndrome that is highly specific fo

59 se may be more important in the aetiology of young-onset dementia than previously believed, and is of

60 Moreover, many of the young-onset dementias are treatable.

61 In a pedigree of a patient with young onset diabetes, several members carry a newly iden

62 Sensitivity analyses showed young-onset diabetes as a significant determinant of ESR

63 mutation (p.G1117E) in the PASK gene from a young-onset diabetes family, which modulates glucose-sti

64 majority (438/597 (73%)) with other types of young-onset diabetes had an HbA1c above the upper limit

65 in the PASK gene that may be associated with young-onset diabetes in humans.

66 ine diabetes exposure or parental history of young-onset diabetes increased a child's absolute risk o

67 ibility, a genome-wide association study for young-onset diabetes was conducted in an American-Indian

68 chanisms and is therefore valid for studying young-onset disease in which genotype does not influence

69 of onset was variable but included cases of young-onset disease.

70 dult data sources are best suited for use in young-onset diseases such as pediatric cancers.

71 DYT1 dystonia is a severe form of young-onset dystonia caused by a mutation in the gene th

72 Young-onset families may therefore represent a group in

73 In conclusion, young-onset families provide both disproportionate evide

74 with an apparent autosomal recessive, novel, young-onset, generalised form of dystonia parkinsonism.

75 widely-expressed co-chaperone AIP, result in young-onset growth hormone secreting pituitary tumours.

76 g protein (AIP) mutation-induced aggressive, young-onset growth hormone-secreting pituitary tumors ar

77 vealed a far higher proportion of cases with young onset (>50%), with a steady decline to the contemp

78 n 10 years (89.4% vs. 76.8%), especially for young-onset HCCs <50 years (79.4% vs. 40.6%), under slig

79 ) had the highest cancer risk, predominantly young-onset head and neck squamous cell carcinomas (medi

80 wing it is also present in two patients with young-onset Huntington's disease (26 and 40 years old at

81 runcating FANCG mutations were identified in young onset (<55 years) pancreatic cancer cases with no

82 of familial aggregation of lung cancer among young onset (<or=55 years of age) lung cancer cases.

83 ngth of the DCM association was greatest for young-onset (<30 years) disease (OR, 4.75; 95% CI, 2.35-

84 ears); and 3 patterns of diabetes, including young onset (mean [SD] age at diabetes, 34.8 [3.6] years

85 rity Onset Diabetes of the Young (MODY) is a young-onset, monogenic form of diabetes without needing

86 of primary progressive aphasia (naPPA) is a young-onset neurodegenerative disorder characterised by

87 ve distinctive clinical features compared to young-onset non-carriers, with more postural symptoms at

88 A young onset of type 2 diabetes is likely to result, in p

89 I has a clear impact on the investigation of young-onset or complex dementia while reducing the overa

90 FLD was associated with an increased risk of young-onset ovarian cancer (adjusted hazard ratio [aHR],

91 the severity of NAFLD increased, the risk of young-onset ovarian cancer tended to increase (aHR, 95%

92 e is known about modifiable risk factors for young-onset ovarian cancer, except for obesity and nulli

93 ndently associated with an increased risk of young-onset ovarian cancer.

94 fatty liver disease (NAFLD) and the risk of young-onset ovarian cancer.

95 ture morbidity and mortality associated with young-onset ovarian cancer.

96 6,319 young women were newly diagnosed with young-onset ovarian cancer.

97 atic mutations of FANCC and FANCG present in young-onset pancreatic cancer.

98 d to the Tracking Parkinson's study, 424 had young-onset Parkinson's disease (age at onset <= 50) and

99 Data were compared with a young-onset Parkinson's disease (YOPD) cohort, matched f

100 Young-onset Parkinson's disease (YOPD), defined by onset

101 reported in two consanguineous families with young-onset Parkinson's disease (YOPD).

102 ive early-onset or juvenile parkinsonism and young-onset Parkinson's disease and also had similaritie

103 ith a fairly pure parkinsonian syndrome (eg, young-onset Parkinson's disease; YOPD) are due to typica

104 near normal longevity of these patients with young onset parkinsonism.

105 T serially to study members of a family with young-onset parkinsonism who are compound heterozygous f

106 se of autosomal recessive juvenile-onset and young-onset parkinsonism.

107 d be considered in the diagnostic work up of young-onset parkinsonism.

108 Young-onset patients in the UK, but not the Japanese coh

109 ods were used to genotype 2005 patients: 302 young-onset patients were fully genotyped with multiplex

110 Of all young-onset patients, 10 (3.3%) carried biallelic mutati

111 In young-onset patients, dominant and recessive mutations w

112 .76, 95% confidence interval: 1.43, 2.15) or young-onset prostatitis (adjusted OR = 1.55, 95% confide

113 istories of sexually transmitted infections, young-onset prostatitis, and frequency of ejaculation, w

114 insulin-reactive BND2 cells in the blood of young-onset T1D donors, which was further enriched in th

115 icity, phenotype, and function of B cells in young-onset T1D.

116 may play a role in the rapid progression of young-onset T1D.

117 Young-onset T2D (YOD) (defined as onset before age 40 ye

118 Here, we review the evidence pertaining to young-onset T2DM and its current and future burden of di

119 The current study reports a GWAS for young-onset T2DM in American Indians.

120 umber of younger adults with T2DM increases, young-onset T2DM is predicted to become a more frequent

121 Furthermore, individuals with young-onset T2DM seem to have a higher risk of complicat

122 n addition, we highlight the associations of young-onset T2DM with premature mortality and morbidity.

123 nger people (aged <40 years), referred to as young-onset T2DM, has a more rapid deterioration of beta

124 first description of a pathologically proved young-onset tauopathy with apparent recessive inheritanc

125 mutation from unaffected family members and young-onset type 1 (T1D) and type 2 diabetes (T2D) and t

126 ts a role for B cells in the pathogenesis of young-onset type 1 diabetes (T1D), wherein rapid progres

127 Genetic susceptibility to young-onset type 1 diabetes is well defined and does not

128 s of the young (MODY), and 463 patients with young-onset type 2 diabetes (nonobese, diagnosed <45 yea

129 /A variant in the 3'-UTR was associated with young-onset type 2 diabetes (odds ratio 2.09 per copy of

130 this variant, were nominally associated with young-onset type 2 diabetes (P = 0.01; odds ratio 3.39)

131 an age, 52.2 years), and 83 individuals with young-onset type 2 diabetes (YT2D), diagnosed at age 45

132 Young-onset type 2 diabetes also affects more individual

133 Furthermore, evidence is accumulating that young-onset type 2 diabetes has a more aggressive diseas

134 with variants that confer susceptibility to young-onset type 2 diabetes in American Indians.

135 8M substitution identified in a patient with young-onset type 2 diabetes may be a rare nonfunctional

136 irm our hypothesis that families segregating young-onset type 2 diabetes represent a more powerful re

137 Optimal prevention of young-onset type 2 diabetes requires identification of t

138 were included and were classified as having young-onset (YO) cancer if diagnosed between ages 20 to